Screening HIV-infected adults in Malawi for anaemia: Impact on eligibility for antiretroviral therapy

International Journal of STD and AIDS

Volumn 24, Issue 6, 2013, Pages 449-453

  Page, I D ^a   McKew, S J ^b   Kudzala, A G ^c   Fullwood, C ^a   van Oosterhout, J J ^c   Bates, I ^d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MALAWI LIVERPOOL WELLCOME TRUST CLINICAL RESEARCH PROGRAMME   (Malawi)

^c UNIVERSITY OF MALAWI   (Malawi)

^d LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

Africa; AIDS; anaemia; antiretroviral therapy; CD4 count; clinical staging; eligibility; haemoglobin; HIV; Malawi; resource poor areas; treatment; treatment threshold

Indexed keywords

ANTIRETROVIRUS AGENT; HEMOGLOBIN;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; BLOOD CHEMISTRY; CD4 LYMPHOCYTE COUNT; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MALAWI; MALE; MEASUREMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; SCREENING TEST; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

AFRICA; AIDS; ANAEMIA; ANTIRETROVIRAL THERAPY; CD4 COUNT; CLINICAL STAGING; ELIGIBILITY; HAEMOGLOBIN; HIV; MALAWI; RESOURCE-POOR AREAS; TREATMENT; TREATMENT THRESHOLD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; ELIGIBILITY DETERMINATION; FEMALE; HEMOGLOBINS; HIV INFECTIONS; HUMANS; MALAWI; MALE; MASS SCREENING; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREVALENCE; YOUNG ADULT;

EID: 84887343619     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1177/0956462412472832     Document Type: Article

References (19)

1. May M,Boulle A,Phiri S, et al.Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes.Lancet. 2010;376:449-57.
2. Boyle DS,Hawkins KR,Steele MS,Singhal M,Cheng X.Emerging technologies for point-of-care CD4 T-lymphocyte counting.Trends Biotechnol. 2011;30:45-54.
3. Severe P,Juste MAJ,Ambroise A, et al.Early versus standard antiretroviral therapy for HIV-infected adults in Haiti.N Engl J Med. 2010;363:257-65.
4. Nzou C,Kambarami RA,Onyango FE,Ndhlovu CE,Chikwasha V.Clinical predictors of low CD4 count among HIV infected pulmonary tuberculosis clients: a health facility-based survey.S Afr Med J. 2010;100:602-5.
5. Owiredu WKBA,Quaye L,Amidu N,Addai-Mensah O.Prevalence of anaemia and immunological markers among Ghanaian HAART-naïve HIV-patients and those on HAART.Afr Health Sci. 2011;11:2-15.
6. Liu KC,Mulindwa J,Giganti MJ, et al.Predictors of CD4 eligibility for antiretroviral therapy initiation among HIV-infected pregnant women in Lusaka, Zambia.J Acquir Immune Defic Syndr. 2011;57:e101-5.
7. Lewis DK,Whitty CJM,Walsh AL, et al.Treatable factors associated with severe anaemia in adults admitted to medical wards in Blantyre, Malawi, an area of high HIV seroprevalence.Trans R Soc Trop Med Hygiene. 2005;99:561-7.
8. Adewuyi JO,Coutts AM,Latif AS,Smith H,Abayomi AE,Moyo AA.Haematologic features of the human immunodeficiency virus (HIV) infection in adult Zimbabweans.Cent Afr J Med. 1999;45:26-30.
9. Adediran IA,Durosinmi MA.Peripheral blood and bone marrow changes in patients with acquired immunodeficiency syndrome.Afr J Med Med Sci. 2006;35:85-91.
10. Ssali F,Stöhr W,Munderi P, et al.Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial.Antivir Ther. 2006;11:741-9.
11. Nacoulma EWC,Some Y,Tieno H, et al.[Haematological parameters evolution during the antiretroviral therapy of HIV infected patients in Burkina-Faso].Bull Soc Pathol Exot. 2007;100:271-4.
12. Erhabor O,Ejele OA,Nwauche CA,Buseri FI.Some haematological parameters in human immunodeficiency virus (HIV) infected Africans: the Nigerian perspective.Niger J Med. 2005;14:33-8.
13. Firnhaber C,Smeaton L,Saukila N, et al.Comparisons of anemia, thrombocytopenia, and neutropenia at initiation of HIV antiretroviral therapy in Africa, Asia, and the Americas.Int J Infect Dis. 2010;14:e1088-92.
14. Medina Lara a,Mundy C,Kandulu J,Chisuwo L,Bates I.Evaluation and costs of different haemoglobin methods for use in district hospitals in Malawi.J Clin Pathol. 2005;58:56-60.
15. Antiviral Therapy for HIV Infection in Adults and Adolescents. Geneva, Switzerland: World Health Organisation; 2010:.
16. Moore DM,Yiannoutsos CT,Musick BS, et al.Determinants of early and late mortality among HIV-infected individuals receiving home-based antiretroviral therapy in rural Uganda.J Acquir Immune Defic Syndr. 2011;58:289-96.
17. Alemu AW,Sebastián MS.Determinants of survival in adult HIV patients on antiretroviral therapy in Oromiyaa, Ethiopia.Global Health Action. 2010;3:5398.
18. Russell EC,Charalambous S,Pemba L,Churchyard GJ,Grant AD,Fielding K.Low haemoglobin predicts early mortality among adults starting antiretroviral therapy in an HIV care programme in South Africa: a cohort study.BMC Public Health. 2010;10:433.
19. Sandison TG,Homsy J,Arinaitwe E, et al.Protective efficacy of co-trimoxazole prophylaxis against malaria in HIV exposed children in rural Uganda: a randomised clinical trial.BMJ (Clin Res ed.). 2011;342:d1617.